1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2022, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 25, 37, 16, 2, 53, 10 and 7 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.
Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Keratoconjunctivitis Sicca (Dry Eye) - Overview
- Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Keratoconjunctivitis Sicca (Dry Eye) - Companies Involved in Therapeutics Development
- Keratoconjunctivitis Sicca (Dry Eye) - Drug Profiles
- Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects
- Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products
- Keratoconjunctivitis Sicca (Dry Eye) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects, 2022
- Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB2 Bio Ltd
- AbbVie Inc
- Abilita Bio Inc
- Actinobac Biomed Inc
- Aerie Pharmaceuticals Inc
- Aldeyra Therapeutics Inc
- Allegro Ophthalmics LLC
- Allgenesis Biotherapeutics Inc
- Allosterix Ltd
- Allysta Pharmaceuticals Inc
- APIRx Pharmaceuticals USA LLC
- Aramis Biosciences Inc
- Ascendia Pharmaceuticals Inc
- Aviara Pharmaceuticals Inc
- Avixgen Inc
- AxeroVision Inc
- Azura Ophthalmics Pty Ltd
- Bessor Pharma LLC
- BRIM Biotechnology Inc
- BSIM Therapeutics SA
- Cambium Medical Technologies LLC
- Cellix Bio Pvt Ltd
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Chong Kun Dang Pharmaceutical Corp
- Cloudbreak Therapeutics LLC
- Curexsys GmbH
- Curigin Co Ltd
- Daewoo Pharmaceutical Co Ltd
- Daewoong Pharmaceutical Co Ltd
- DHP Korea Co Ltd
- Dompe Farmaceutici SpA
- EncuraGen Co Ltd
- Eye Bio Korea Co Ltd
- FirstString Research Inc
- GL Pharm Tech Corp
- Glaukos Corp
- Glia LLC
- H4Orphan Pharma
- HanAll Biopharma Co Ltd
- Huons Co Ltd
- Huons Global Co Ltd
- IACTA Pharmaceuticals Inc
- Icure Pharmaceutical Inc
- Ildong Pharmaceutical Co Ltd
- Intratus Inc
- Invitrx Therapeutics Inc
- Ipsen SA
- IVIEW Therapeutics Inc
- Japan Tobacco Inc
- Juvenescence UK Ltd
- Kala Pharmaceuticals Inc
- Kiora Pharmaceuticals Inc
- Kowa Co Ltd
- Kukje Pharmaceutical Industry Co Ltd
- Laboratoires Thea SA
- Link Biologics Ltd
- LTT Bio-Pharma Co Ltd
- Marinomed Biotech AG
- MC2 Therapeutics AS
- Medicon Pharmaceuticals Inc
- MediPrint Ophthalmics Inc
- MeiraGTx Holdings Plc
- Merck & Co Inc
- Mimetogen Pharmaceuticals Inc
- Mitotech SA
- MyX Therapeutics Inc
- Nanomerics Ltd
- Neuroptika Inc
- NicOx SA
- Ningbo Xijian Pharmaceutical Technology Co Ltd
- NovaCell Technology Inc
- Novaliq GmbH
- Novartis AG
- Noveome Biotherapeutics Inc
- OccuRx Pty Ltd
- Ocular Therapeutix Inc
- Oculis SA
- Ocumension Therapeutics
- OKYO Pharma Ltd
- OncoNOx ApS
- Ophrx Ltd
- Oyster Point Pharma Inc
- Palatin Technologies Inc
- Panag Pharma Inc
- PharmaResearch Co Ltd
- Pinotbio Inc
- Pleryon Therapeutics Ltd
- Proteris Biotech Inc
- Protokinetix Inc
- Qilu Pharmaceutical Co Ltd
- Quorum Innovations LLC
- Redwood Pharma AB
- RegeneRx Biopharmaceuticals Inc
- Reven Holdings Inc
- Rhizen Pharmaceuticals SA
- RHNanopharmacuticals LLC
- RiniSight Inc
- Rudacure Co Ltd
- Samjin Pharm Co Ltd
- Santen Pharmaceutical Co Ltd
- SCAI Therapeutics
- Seinda Pharmaceutical Guangzhou Corp
- Senju Pharmaceutical Co Ltd
- Serentrix LLC
- Shenzhen Evergreen Therapeutics Co Ltd
- SIFI SpA
- Silk Technologies Ltd
- Sinobioway Biomedical Co Ltd
- Skye Bioscience Inc
- Sol-Gel Technologies Ltd
- Stuart Therapeutics Inc
- Sun Pharmaceutical Industries Ltd
- Surface Pharmaceuticals Inc
- Surrozen Inc
- Sylentis SAU
- TaeJoon Pharmaceuticals Co Ltd
- TagCyx Biotechnologies
- Tarsius Pharma Ltd
- TearSolutions Inc
- Tetra Bio-Pharma Inc
- Vanda Pharmaceuticals Inc
- Viva Vision Biotech
- Yuyu Pharma Inc
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd
- Zhuhai Qiwei Biotechnology Co Ltd
